Cocrystal Pharma: Phase 1 CDI-988 well tolerated; Phase 1b planned for norovirus

Cocrystal Pharma, Inc.

All CDI-988 doses (100-1200 mg) well tolerated in Phase 1 SAD and MAD cohorts; no severe AEs.
Treatment-emergent AEs in SAD: 28% (10/36) CDI-988 vs 40% (4/10) placebo; MAD: 53% (19/36) vs 92% (11/12).
Company expects to initiate Phase 1b challenge study in norovirus-infected healthy subjects later in 2025.
Headache most common AE; no clinically relevant ECG changes or pathology results reported.
CDI-988 targets 3CL viral proteases; potential prophylaxis/treatment for norovirus and coronaviruses.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.